Abstract
Positive HLA-B*5701 genotype has recently been identified as the main genetic risk factor for flucloxacillin drug-induced liver injury (DILI). Testing for HLA-B*5701 is routine in many HIV clinics to identify those at risk of hypersensitivity reaction (HSR) to abacavir. Considering the high prevalence of soft-tissue infections in HIV patients, we conducted a retrospective study to investigate whether flucloxacillin use was associated with adverse events in HIV patients known to be HLA-B*5701 positive.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Anti-Bacterial Agents / administration & dosage
-
Anti-Bacterial Agents / adverse effects*
-
Anti-HIV Agents / therapeutic use
-
Chemical and Drug Induced Liver Injury / etiology*
-
Chemical and Drug Induced Liver Injury / genetics
-
Chemical and Drug Induced Liver Injury / immunology
-
Drug Hypersensitivity / genetics
-
Drug Hypersensitivity / immunology
-
Female
-
Floxacillin / administration & dosage
-
Floxacillin / adverse effects*
-
Genotype
-
HIV Infections / drug therapy
-
HIV Infections / genetics
-
HIV Infections / immunology*
-
HLA-B Antigens / drug effects*
-
HLA-B Antigens / genetics
-
Humans
-
Male
-
Middle Aged
-
Retrospective Studies
-
Risk Factors
Substances
-
Anti-Bacterial Agents
-
Anti-HIV Agents
-
HLA-B Antigens
-
HLA-B*57:01 antigen
-
Floxacillin